Oren Livnat
Stock Analyst at HC Wainwright & Co.
(3.61)
# 804
Out of 4,876 analysts
140
Total ratings
44.44%
Success rate
7.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Oren Livnat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCRX Pacira BioSciences | Maintains: Buy | $48 → $65 | $23.60 | +175.42% | 20 | Apr 8, 2025 | |
| VRCA Verrica Pharmaceuticals | Reiterates: Neutral | n/a | $0.58 | - | 12 | Apr 8, 2025 | |
| COLL Collegium Pharmaceutical | Reiterates: Buy | $50 | $29.90 | +67.22% | 10 | Mar 24, 2025 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $13 | $5.66 | +120.85% | 7 | Mar 19, 2025 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $94 | $65.90 | +42.64% | 13 | Mar 17, 2025 | |
| ZVRA Zevra Therapeutics | Reiterates: Buy | $20 | $9.28 | +115.52% | 9 | Mar 13, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $200 → $217 | $107.59 | +101.69% | 17 | Mar 10, 2025 | |
| XERS Xeris Biopharma Holdings | Reiterates: Buy | $6.6 → $8 | $4.74 | +68.78% | 11 | Mar 7, 2025 | |
| AVDL Avadel Pharmaceuticals | Reiterates: Buy | $21 | $9.29 | +126.17% | 16 | Mar 4, 2025 | |
| TARS Tarsus Pharmaceuticals | Reiterates: Buy | $73 | $40.29 | +81.21% | 9 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.94 | +308.16% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7.5 | $3.77 | +98.94% | 6 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $8 | $0.74 | +986.22% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $60 | $3.22 | +1,747.83% | 5 | Aug 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $252 → $198 | $1.62 | +12,122.22% | 2 | May 7, 2021 |
Pacira BioSciences
Apr 8, 2025
Maintains: Buy
Price Target: $48 → $65
Current: $23.60
Upside: +175.42%
Verrica Pharmaceuticals
Apr 8, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.58
Upside: -
Collegium Pharmaceutical
Mar 24, 2025
Reiterates: Buy
Price Target: $50
Current: $29.90
Upside: +67.22%
Trevi Therapeutics
Mar 19, 2025
Reiterates: Buy
Price Target: $13
Current: $5.66
Upside: +120.85%
ANI Pharmaceuticals
Mar 17, 2025
Reiterates: Buy
Price Target: $94
Current: $65.90
Upside: +42.64%
Zevra Therapeutics
Mar 13, 2025
Reiterates: Buy
Price Target: $20
Current: $9.28
Upside: +115.52%
Jazz Pharmaceuticals
Mar 10, 2025
Maintains: Buy
Price Target: $200 → $217
Current: $107.59
Upside: +101.69%
Xeris Biopharma Holdings
Mar 7, 2025
Reiterates: Buy
Price Target: $6.6 → $8
Current: $4.74
Upside: +68.78%
Avadel Pharmaceuticals
Mar 4, 2025
Reiterates: Buy
Price Target: $21
Current: $9.29
Upside: +126.17%
Tarsus Pharmaceuticals
Feb 26, 2025
Reiterates: Buy
Price Target: $73
Current: $40.29
Upside: +81.21%
Feb 18, 2025
Reiterates: Buy
Price Target: $12
Current: $2.94
Upside: +308.16%
Jan 4, 2024
Reiterates: Buy
Price Target: $7.5
Current: $3.77
Upside: +98.94%
May 13, 2022
Maintains: Buy
Price Target: $14 → $8
Current: $0.74
Upside: +986.22%
Aug 26, 2021
Maintains: Buy
Price Target: $43 → $60
Current: $3.22
Upside: +1,747.83%
May 7, 2021
Maintains: Buy
Price Target: $252 → $198
Current: $1.62
Upside: +12,122.22%